Partnership Opportunities
Biocatalysis as a means for drug development has transitioned to becoming first priority for the biopharma industry in ensuring quality drugs are produced within critical timeframes, with companies such as Eli Lilly and Novo Nordisk heavily investing.
Addressing end-to-end operations spanning from enzyme discovery, engineering and biocatalysis, the 4th Applied Biocatalysis & Enzyme Engineering Summit was your gateway to achieving your commercial goals and ideal partnerships with established and expanding biopharma and specialty chemical manufacturers.
In collaboration with the likes of Sanofi, Merck, Novo Nordisk, Pfizer, Amgen, and Boehringer Ingelheim, we hosted the only industry-led meeting exploring biocatalysis potential for newer modalities and small molecule development.
Previous Partners:
Experts Still Need Your Help With:
- Large-scale biocatalysis to enable successful processing resulting in high yields and waste management
- Enzyme supply with diverse opportunities to enable biocatalysis compatibility
- Enzyme screening services to facilitate decision-making and speed up selection
- Enzyme engineering capabilities to futureproof biocatalysis
- Biocatalysis equipment to allow for successful in-house processing
Why Partner?
Establish your solutions ahead of 80+ industry professionals to engage maximal interest and meet commercial objectives
Engage in a 3-day networking and interactive opportunity to connect with all relevant players and tailor to current demands
Communicate your service flexibility and cross-modality applications to a diverse audience to connect with multiple industries
Be a prominent participant at the only meeting in the industry covering end-to-end engineering and biocatalysis beyond small molecule development
Audience Summary:
